Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.

BACKGROUND: The novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line intranasal antihistamine spray (AZE) in Russian seasonal allergic rhinitis (SAR) patients. METHODS: Moderate-to-severe SAR/rhinoconjunctivitis patients (n = 149; aged 18-65 years) were randomized to receive MP-AzeFlu (137/50 µg AZE/FP per spray) or AZE (137 µg/spray), both as 1 spray/nostril twice daily, in a multicenter, open-label, 14-day, parallel-group trial. The primary outcome was change from baseline in morning and evening reflective total nasal symptom score (rTNSS). Secondary end points included: change from baseline in reflective total ocular symptom score (rTOSS), reflective total of 7 symptom scores (rT7SS), 28-item Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) overall score, and EuroQol-5D (EQ-5D) questionnaire score. RESULTS: When compared with AZE-treated patients, those treated with MP-AzeFlu experienced significantly greater reductions in rTNSS (difference: -2.47; 95% confidence interval [CI] -3.65 to -1.30; p < 0.001), rTOSS (difference: -1.62; 95% CI -2.32 to -0.92; p < 0.001), and rT7SS (difference: -4.34; 95% CI -5.98 to -2.70; p < 0.001). Superior relief observed on day 2 with MP-AzeFlu versus AZE was sustained throughout the study. MP-AzeFlu-treated patients experienced a greater improvement in QoL than AZE-treated patients as measured by overall RQLQ score (mean ± SD 2.91 ± 1.08 vs. 2.05 ± 1.15) and EQ-5D score (mean ± SD 87.4 ± 10.3 vs. 83.0 ± 12.8). MP-AzeFlu was well tolerated. CONCLUSIONS: MP-AzeFlu was superior to AZE in reducing moderate-to-severe SAR symptoms, providing earlier and more complete symptom relief.

Temperature dependence of speed of sound and attenuation of porcine left ventricular myocardium.

The temperature dependence of soft tissue acoustic properties is relevant for monitoring tissue hyperthermia. In the current work, the propagation speed and attenuation of healthy porcine left ventricular myocardium (N=5) was investigated in a frequency range relevant for clinical diagnostic imaging, i.e. 2.5-13.0MHz. Each tissue sample was held in a water bath at a temperature T=25°C, heated to 45°C, and allowed to cool back down to 25°C. Due to initial tissue swelling, the data for decreasing temperatures was considered more reliable. In this case, the slope of the phase velocity versus temperature relation was measured to be 1.10±0.04m/s/°C, and the slope of the attenuation was -0.11±0.04dB/cm/°C at 10MHz, or -0.0041±0.0015dB/cm/MHz1.4336/°C as a function of frequency.

Attenuation estimation by repeatedly solving the forward scattering problem.

Estimation of the attenuation is important in medical ultrasound not only for correct time-gain compensation but also for tissue characterization. In this paper, the feasibility of a new method for attenuation estimation is tested. The proposed method estimates the attenuation by repeatedly solving the forward wave propagation problem and matching the simulated signals to the measured ones. This approach allows avoiding common assumptions made by other methodologies and potentially allows to account and correct for other acoustic effects that may bias the attenuation estimate. The performance of the method was validated on simulated data and on data recorded in tissue mimicking phantoms with known attenuation properties, and was compared to the spectral-shift and spectral-difference methods. Simulation results showed the different methods to have good accuracy when noise-free signals were considered (the average relative error of the attenuation estimation did not exceed 15%). However, the accuracy of the conventional methods decreased rapidly in the presence of measurement noise and varying scatterer concentration, while the relative error of the proposed method remained below 15%. Furthermore, the proposed method outperformed conventional attenuation estimators in the experimental phantom study, where its average error was 8%, while the average error of the spectral-shift and spectral-difference methods was 26% and 32%, respectively. In summary, these findings demonstrate the feasibility of the proposed approach and motivate us to refine the method for solving more general problems.

Methyl-cellulose powder for prevention and management of nasal symptoms.

INTRODUCTION: HPMC-p, an inert micronized powder form of hydroxy-propyl-methyl-cellulose, when insufflated nasally, provides a natural barrier against pollen allergens and noxious agents. This overview assesses the efficacy and safety of this patented powder product and delivery system without an analogue among the cellulose derivatives. Areas covered: Twenty-six studies with HPMC-p were critically appraised to obtain an updated characteristic of the product. Most studies assessed the efficacy of HPMC-p as a nasal barrier enforcing measure: one experimental setup evaluated its ability to prevent or delay the diffusion of allergen through it, two clinical studies used allergen provocation tests, and the remaining relied on clinical criteria in open real world or placebo controlled designs. Two studies checked if HPMC-p could enhance the efficacy of drugs applied nasally to treat local symptoms. The studies, using either nasal allergen challenge or natural exposure of patients to environmental allergen, support the hypothesis that HPMC-p possesses barrier enforcing properties. Also, acute and clinical experiments indicated that intra-nasal application of HPMC-p following local relief medications enhances their ability to suppress symptoms and reduces their long-term use. Expert commentary: Nasal insufflation of HPMC-p provides a mucosal barrier, reducing the nasal symptoms and enhancing the effects of local relief medications.

Extension of the angular spectrum method to model the pressure field of a cylindrically curved array transducer.

An extension to the angular spectrum approach for modelling pressure fields of a cylindrically curved array transducer is described in this paper. The proposed technique is based on representing the curved transducer surface as a set of planar elements whose contributions are combined at a selected intermediate plane from which the field is further propagated using the conventional angular spectrum approach. The accuracy of the proposed technique is validated through comparison with Field II simulations.

Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.

Neisseria meningitidis is the leading cause of bacterial invasive infections in people aged <15 years in the Russian Federation. The aim of this phase III, multicenter, open-label study was to assess the immunogenicity and safety of the quadrivalent meningococcal CRM197-conjugate vaccine MenACWY when administered to healthy Russian subjects aged 2 years and above. A total of 197 subjects were immunized with a single dose of the vaccine, and serogroup-specific serum bactericidal activity was measured pre and 1-month post-vaccination with human complement (hSBA) serum titers. Regardless of baseline serostatus, 1 month after a single dose of MenACWY-CRM197 85% (95%CI, 79-90%) of subjects showed serologic response against serogroup A, 74% (67-80%) against serogroup C, 60% (53-67%) against serogroup W, and 83% (77-88%) against serogroup Y. The percentage of subjects with hSBA titers ≥ 1:8 1 month after vaccination was 89% (83-93%) against serogroup A, 84% (78-89%) against serogroup C, 97% (93-99%) against serogroup W, and 88% (82-92%) against serogroup Y. Comparable results were obtained across all subjects: children (2 to 10 years), adolescents (11 to 17 years), and adults (≥18 years). The MenACWY-CRM197 vaccine showed an acceptable safety profile and was well tolerated across all age groups, with no serious adverse events or deaths reported during the study. In conclusion, a single dose of meningococcal MenACWY-CRM197 vaccine is immunogenic and has an acceptable safety profile, provides a broad protection against the most frequent epidemic serogroups, and is a suitable alternative to currently available unconjugated monovalent or bivalent polysaccharide vaccines in Russia.